HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, a clinical-stage biopharmaceutical company, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. The presentation will cover HIL-214, an investigational vaccine for moderate-to-severe norovirus-related acute gastroenteritis, and the ongoing Phase 2b study NEST-IN1. The event will be held at the Westin St. Francis Hotel in San Francisco, starting at 4:30 p.m. EST. HilleVax aims to address the significant health burden of norovirus, which affects millions globally.

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023, at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.

Presentation details:
Date:	Monday, January 9, 2023
Time:	1:30 – 2:10 p.m. Pacific Standard Time (PST)
Moderator:	Eric Joseph, Ph.D.
Location:	Borgia Room, Westin St. Francis Hotel, San Francisco
HilleVax Participant:	Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer
Webcast & Audio Visual:	https://jpmorgan.metameetings.net/events/healthcare23/sessions/43891-hillevax/webcast?gpu_only=true&kiosk=true

About HilleVax

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a VLP based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Contact:

Shane Maltbie
IR@hillevax.com
+1-617-213-5054

FAQ

When will HilleVax present at the J.P. Morgan Healthcare Conference?

HilleVax will present on January 9, 2023, at 4:30 p.m. EST.

What is HIL-214?

HIL-214 is an investigational virus-like particle vaccine for preventing moderate-to-severe norovirus-related acute gastroenteritis.

Where will the presentation take place?

The presentation will be held at the Borgia Room, Westin St. Francis Hotel, San Francisco.

Who is moderating the HilleVax presentation?

Dr. Eric Joseph will moderate the HilleVax presentation.

What is the significance of norovirus according to HilleVax?

Norovirus causes over 700 million cases of acute gastroenteritis and approximately 200,000 deaths annually.